Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising pharmaceuticals. The company has a track record of innovation and success in developing new oral drug delivery systems.

Mayne Pharma

Domain Not Resolving

HSTS

DNSSEC

jsDelivr

CloudFront

BootstrapCDN

Microsoft

Smart App Banner

SiteGround CAPTCHA

Zoho Hosting

Finance and Administration

Aaron Gray

Owner

Chris Harig

VP of Analytical Development, GPD

Kym Rispress

Chief Financial Officer

Peter Paltoglou

Business Management

Scott Richards

Vice President, Group Human Resources

Andrew Herdman

Vice President, Generic Product Sales

Beth Hamilton

Executive Vice President Specialty Products Division

Brant Schofield

Executive Vice President, Generic Products Division

Daniel Moore

Executive Vice President, Women’s Health

Donny Pearl

Bruce Robinson

Ian Scholes

Phil Hodges

Nancy Dolan

Ron Best

Bruce Mathieson

Roger Corbett

John Ross

Executive Vice President, Metrics Contract Services

Stefan Cross

President, Mayne Pharma USA

Craig Boyd

Executive Vice President, US Generic Products

Andy McLenaghan

Executive Vice President, US Specialty Brands

Eric Evans

Chief Financial Officer, Mayne Pharma USA

CEO, Managing Director & Founder

Mark Cansdale

CFO, Secretary

A clinical stage biopharmaceutical company.

New South Wales Investors

Investors Active in Tampa Bay Area

Investors Active in Tampa, Florida

Australia Companies With More Than $10M in Revenue

Mayne Pharma Group Limited (Mayne Pharma) is an Australian specialist pharmaceutical company with an intellectual property portfolio built around the optimisation and delivery of oral dosage form drugs.
Mayne Pharma has a long and successful history of developing and commercializing improved pharmaceuticals and has launched and marketed numerous products through partnerships with licensees in various countries around the world. Mayne Pharma focuses on delivering to patients improved versions of existing drugs in order to advance safety, efficacy or ease of administration.

Post-IPO Equity - Mayne Pharma

Salisbury

New South Wales

Australia

Oceania

Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringement

Australia's Mayne Pharma gains on reaffirming positive outlook

Favourable Signals For Mayne Pharma Group: Numerous Insiders Acquired Stock

Investors in Mayne Pharma Group (ASX:MYX) have seen respectable returns of 93% over the past year

Mithra sells shares in Mayne Pharma

While institutions invested in Mayne Pharma Group Limited (ASX:MYX) benefited from last week's 12% gain, retail ...

Mayne Pharma Targets A Breakeven Run Rate In 1Hfy24 For Nextstellis

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

Mayne Pharma and Mithra Announce TGA Approval of NEXTSTELLIS® Oral Contraceptive

United States

North America

Bangladesh

Asia

India

Turkey

Europe

HTML5

HubSpot Marketing Hub

Wordpress

Symantec Email Security.Cloud

Office 365

jQuery

Adobe Fonts

Modernizr

Facebook Comments

Bootstrap

Mayne Pharma owns Metrics Contract Services

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Mayne Pharma Group Limited

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Sep 29, 2024 6:12 PM	b4dc2c7a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general	Sep 29, 2024 6:12 PM	a777438f
news processing advanced	general
crunchbase trigger	general	Oct 28, 2024 1:50 PM	865872d5
crunchbase profile	general	Oct 29, 2024 9:38 AM	563931ec
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	b6a97209
peers	general	Sep 29, 2024 6:12 PM	370e8184
news basic	general	Sep 29, 2024 6:12 PM	6f7ab03f
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

MYX

COM:MAYNEPHARMA

Mayne Pharma

Last Close

4.43

08/11 05:10

Market Cap

362.42M

Beta: -

Volume Today

381.98K

Avg: -